Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Hye Ryun Kim"'
Autor:
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, Hee Kyung Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of
Publikováno v:
Cell & Bioscience, Vol 11, Iss 1, Pp 1-12 (2021)
Cell & Bioscience
Cell & Bioscience
Background Recently, we demonstrated that estrogen (E2) induces early growth response 1 (Egr1) to mediate its actions on the uterine epithelium by controlling progesterone receptor signaling for successful embryo implantation. EGR1 is a transcription
Autor:
Minkyu Jung, Joohyuk Sohn, Seung Hoon Beom, Hye Jin Choi, Hyun Cheol Chung, Jii Bum Lee, Joong Bae Ahn, Hye Ryun Kim, Gun Min Kim, Sun Young Rha
Publikováno v:
Investigational New Drugs
SummaryTAS-117 is a potent and selective allosteric pan-v-akt murine thymoma viral oncogene homolog (Akt) inhibitor. We conducted a single-arm single-center phase 2 study of TAS-117 in heavily treated patients with tumors refractory to systemic chemo
Autor:
Sang Jun Ha, Daehee Hwang, Eun Chang Choi, Min Hee Hong, Se-Heon Kim, Hye Ryun Kim, Sun Min Lim, Sun Och Yoon, Da Hee Kim, Yoon Woo Koh, Sehyun Chae
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2741-2750
We aimed to investigate the prognostic value of multiple immune cell markers including programmed death-ligand 1 (PD-L1) and poliovirus receptor (PVR) in head and neck squamous cell carcinoma (HNSCC) using archival tumor tissues METHODS: Patients dia
Autor:
Kyoung Ho Pyo, Hong In Yoon, Y. G. Kim, Jaehyung Jung, In-Ho Seo, Chun-Bong Synn, Su-Hyung Park, Soonmyung Paik, Yong Il Lee, Jeong-Eun Kwak, Yun Jeong Lee, Kyung Hwan Kim, Seongjin Choi, Hyo Sup Shim, Chang Gon Kim, Min Hee Hong, Hye Ryun Kim, Ellen Janine Kim, Beung-Chul Ahn, Eui-Cheol Shin
Publikováno v:
European Journal of Cancer. 143:113-126
Background The predictive value of immune monitoring with circulating CD8+ T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to investig
Autor:
Hye Ryun Kim, Hyun Chang, Keun-Wook Lee, Myung-Ju Ahn, Seong Hoon Shin, Ho Jung An, Sung-Bae Kim, Sang Hoon Chun, Yun-Gyoo Lee, Ji Hyun Park, Kyoung Eun Lee, In Gyu Hwang, Keon Uk Park, Bhumsuk Keam
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical bi
Autor:
Huamao M. Lin, Myung-Ju Ahn, Pingkuan Zhang, Angelo Delmonte, Marcello Tiseo, D. Ross Camidge, Frank Griesinger, Scott N. Gettinger, Dong Wan Kim, Maria Rosario Garcia Campelo, Maximilian Hochmair, Enriqueta Felip, Ki Hyeong Lee, Alexander I. Spira, Q. Ni, Neeraj Gupta, Michael J. Hanley, James Chih-Hsin Yang, Hye Ryun Kim, Sanjay Popat, Ji Youn Han, Raffaele Califano
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de pulmó; Brigatinib; Estudi ALTA-1L Cáncer de pulmón; Brigatinib; Estudio ALTA-1L Lung cancer; Brigatinib; ALTA-1L study PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-f
Autor:
A. Roshak, Chae Won Park, Matthew V. Lorenzi, Seong Gu Heo, Min Hee Hong, Mi Ran Yun, Sun Min Lim, Soo-Hwan Lee, Meena Thayu, Kyoung Ho Pyo, Byoung Chul Cho, Seo Yoon Jeong, Hye Ryun Kim, Seok Young Kim, S.M. Lim, J.C. Curtin, Jiyeon Yun, Jae Hwan Kim, Roland Elmar Knoblauch
Publikováno v:
Cancer Discovery. 10:1194-1209
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activi
Autor:
Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, Bhumsuk Keam
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
BMC Cancer
Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Met
Autor:
Sang We Kim, Young Joo Min, Gyeong Won Lee, Dong Wan Kim, Jin Seok Ahn, Ki Hyeong Lee, Byoung Chul Cho, Jong Seok Lee, Myung-Ju Ahn, Sung Sook Lee, Jin Soo Kim, Dae Ho Lee, Eun Kyung Cho, Jong Mu Sun, Sohee Kim, Joo Hang Kim, Min Hee Hong, Hye Ryun Kim, Ji Youn Han, Yun Gyoo Lee, Heung Tae Kim
Publikováno v:
The Lancet Oncology. 20:1681-1690
Summary Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs. We assessed the safety, tolerability, pharmacoki